Thierry Chevallier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thierry Chevallier has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
A. Dupeyron
Département de Médecine Physique et de Réadaptation, CHU de Nîmes, 30029 Nîmes, France
1 shared publicationAdeline Aime
Department of Visceral and Endocrine Surgery, Bégin Army Teaching Hospital, Saint-Mande, France
1 shared publicationAdrien Schvartz
Laboratory of Single-Cell Inflammatory Responses and multi-OMICs Networks, Imagine Institute, U1163, Paris, France
1 shared publication- Alain Ruffion
Urology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Cancer Innovation Center (EA 3738 CICLY), Lyon Sud Medical School, University of Lyon 1, Lyon, France
1 shared publication - Alexandra Masson-Lecomte
Saint-Louis Hospital 1 Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute Paris, France
1 shared publication Alison Foote
Department of Digestive and Emergency Surgery, Grenoble Alpes University Hospital, Grenoble, France
1 shared publication
Latest Publications
- Open Access
IgA1 hinge-region O-glycoform signatures associated with disease phase and kidney involvement in pediatric IgA vasculitis: a cross-sectional mass-spectrometry study
Background: IgA vasculitis (IgAV) is the most common systemic vasculitis in children, and its prognosis is largely determined by renal involvement (IgAV nephritis). No routine blood test identifies IgAV or stratifies the risk of nephritis, although aberrant O-glycosylation of the IgA1 hinge region is central to its pathogenesis. We developed a mass-spectrometry assay to profile IgA1 hinge O-glycoforms and define signatures of disease activity and renal involvement. Methods: IgA was affinity-purified from 5 µL of plasma from 91 children (27 with acute IgAV, 26 in remission, and 38 age-matched healthy controls; 24 with and 29 without nephritis), trypsin-digested, and hinge-region O-glycopeptides were quantified by LC-MS. Sixty-nine glycoforms were normalized to a total-IgA1 tryptic peptide. Duplicate measurements showed good analytical repeatability, with a median coefficient of variation of 6%. Groups were compared using Mann–Whitney and Kruskal–Wallis tests (Benjamini– Hochberg FDR). Discrimination was assessed by ROC analysis and cross-validated logistic regression panels. Results: Acute IgAV showed broad remodeling of the hinge glycoform profile (35 glycoforms differed with excellent discrimination (AUC 0.93–0.95) for the best ones), with an increase in low-sialylated, agalactosylated species and a decrease in complex sialylated species. The profile was normalized in remission (no glycoform differed from the controls). Two distinct renal patterns emerged: disease-associated glycoforms already altered without nephritis and renal-specific glycoforms altered only in nephritis (H2N2S1, H3N3S5, H3N4S4, and H4N4S3). A four-marker panel discriminated nephritis among IgAV children with a cross-validated AUC of 0.86 (IC 95 % 0.75–0.94). Conclusions: A single mass-spectrometry assay, from a small blood volume, captures an IgAV-associated IgA1 hinge O-glycoform signature that normalizes in remission, together with a distinct renal involvement associated signature. These findings identify candidate IgA1 O-glycoform signatures associated with IgAV activity and documented renal involvement. Prospective longitudinal studies are required to determine whether the renal-associated panel can predict subsequent nephritis.
Open AccessIgA1 hinge-region O-glycoform signatures associated with disease phase and kidney involvement in pediatric IgA vasculitis: a cross-sectional mass-spectrometry study
Background: IgA vasculitis (IgAV) is the most common systemic vasculitis in children, and its prognosis is largely determined by renal involvement (IgAV nephritis). No routine blood test identifies IgAV or stratifies the risk of nephritis, although aberrant O-glycosylation of the IgA1 hinge region is central to its pathogenesis. We developed a mass-spectrometry assay to profile IgA1 hinge O-glycoforms and define signatures of disease activity and renal involvement. Methods: IgA was affinity-purified from 5 µL of plasma from 91 children (27 with acute IgAV, 26 in remission, and 38 age-matched healthy controls; 24 with and 29 without nephritis), trypsin-digested, and hinge-region O-glycopeptides were quantified by LC-MS. Sixty-nine glycoforms were normalized to a total-IgA1 tryptic peptide. Duplicate measurements showed good analytical repeatability, with a median coefficient of variation of 6%. Groups were compared using Mann–Whitney and Kruskal–Wallis tests (Benjamini– Hochberg FDR). Discrimination was assessed by ROC analysis and cross-validated logistic regression panels. Results: Acute IgAV showed broad remodeling of the hinge glycoform profile (35 glycoforms differed with excellent discrimination (AUC 0.93–0.95) for the best ones), with an increase in low-sialylated, agalactosylated species and a decrease in complex sialylated species. The profile was normalized in remission (no glycoform differed from the controls). Two distinct renal patterns emerged: disease-associated glycoforms already altered without nephritis and renal-specific glycoforms altered only in nephritis (H2N2S1, H3N3S5, H3N4S4, and H4N4S3). A four-marker panel discriminated nephritis among IgAV children with a cross-validated AUC of 0.86 (IC 95 % 0.75–0.94). Conclusions: A single mass-spectrometry assay, from a small blood volume, captures an IgAV-associated IgA1 hinge O-glycoform signature that normalizes in remission, together with a distinct renal involvement associated signature. These findings identify candidate IgA1 O-glycoform signatures associated with IgAV activity and documented renal involvement. Prospective longitudinal studies are required to determine whether the renal-associated panel can predict subsequent nephritis.
- 17 December 2025
- Published by Taylor & Francis in Climacteric
- Vol. 29 (2) , 293-299
Safety and performance of photobiomodulation delivered by vaginal probe in patients with genitourinary syndrome of menopause
Genitourinary syndrome of menopause (GSM) has a negative impact on quality of life. Treatments for GSM are largely hormonal, yet some patients remain symptomatic after recommended treatments. Photobiomodulation therapy (PBMT) is a promising non-hormonal technique. In this prospective, first-in-human, medical device safety study, postmenopausal patients with pelvic pain due to vaginal atrophy after failure of non-invasive therapies for >3 months were recruited. Exclusion criteria included pelvic pain of physical and/or psychological origin, treatment for cancer or immunosuppression. Patients received six weekly PBMT sessions using the MILTA GYNECO vaginal probe (PHYSIOQUANTA). The primary outcome was device safety, according to patient-reported adverse events. Secondary outcomes were vaginal mucosal health (vaginal health index [VHI]), pain (0-10 visual analog scale), vaginal flora and patient satisfaction (Patient Global Impression of Change [PGI-C]). Twenty-five patients were recruited and analyzed, with an average age of 58.7 years. In total, 148 adverse events were declared, of which 146 were minor (grade I) and most were for heat sensation (89.2%). Significant improvements were found in pain during intercourse (7.65 [±1.95] before versus 3.89 [±2.44] after, p > 0.0001) and in vaginal health according to the VHI score (12.68 [±4.20] before versus 17.63 [±4.35] after, p > 0.0001). According to the PGI-C score, most patients rated their condition as improved. Even when applying a broad definition for adverse events, these preliminary data suggested that PBMT using the MILTA GYNECO vaginal probe was safe, with high patient satisfaction. The next step is to assess the efficacity of the medical device in a randomized trial.
- 17 December 2025
- Published by Taylor & Francis in Climacteric
- Vol. 29 (2) , 293-299
Safety and performance of photobiomodulation delivered by vaginal probe in patients with genitourinary syndrome of menopause
Genitourinary syndrome of menopause (GSM) has a negative impact on quality of life. Treatments for GSM are largely hormonal, yet some patients remain symptomatic after recommended treatments. Photobiomodulation therapy (PBMT) is a promising non-hormonal technique. In this prospective, first-in-human, medical device safety study, postmenopausal patients with pelvic pain due to vaginal atrophy after failure of non-invasive therapies for >3 months were recruited. Exclusion criteria included pelvic pain of physical and/or psychological origin, treatment for cancer or immunosuppression. Patients received six weekly PBMT sessions using the MILTA GYNECO vaginal probe (PHYSIOQUANTA). The primary outcome was device safety, according to patient-reported adverse events. Secondary outcomes were vaginal mucosal health (vaginal health index [VHI]), pain (0-10 visual analog scale), vaginal flora and patient satisfaction (Patient Global Impression of Change [PGI-C]). Twenty-five patients were recruited and analyzed, with an average age of 58.7 years. In total, 148 adverse events were declared, of which 146 were minor (grade I) and most were for heat sensation (89.2%). Significant improvements were found in pain during intercourse (7.65 [±1.95] before versus 3.89 [±2.44] after, p > 0.0001) and in vaginal health according to the VHI score (12.68 [±4.20] before versus 17.63 [±4.35] after, p > 0.0001). According to the PGI-C score, most patients rated their condition as improved. Even when applying a broad definition for adverse events, these preliminary data suggested that PBMT using the MILTA GYNECO vaginal probe was safe, with high patient satisfaction. The next step is to assess the efficacity of the medical device in a randomized trial.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (13) , 1578-1586
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial
PURPOSE: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. PATIENTS AND METHODS: This phase II trial (ClinicalTrials.gov identifier: NCT04617756 ) included patients with nonmetastatic, high-grade UTUC, on the basis of the ureteroscopic biopsy or urine cytology, and/or infiltrative aspect of the renal pelvis/ureteral wall by computed tomography imaging. Before RNU, patients received durvalumab plus gemcitabine/cisplatin (cohort 1) or durvalumab plus gemcitabine/carboplatin (cohort 2) once every 3 weeks for a total of four cycles (cohort choice on the basis of the glomerular filtration rate). The primary objective was the pathologic complete response (ypT0) rate in each cohort. RESULTS: Fifty patients were enrolled between 2021 and 2024 (31 in cohort 1; 19 in cohort 2). Median age was 68 years (range, 38-79), and 59% were men. Forty-five patients received four cycles of treatment, three patients three cycles, and one patient two cycles. Five patients switched to carboplatin during treatment. At surgery (N = 45 patients), rates of pT0 were 13% (4/29) in cohort 1 and 5% (1/19) in cohort 2. Fifty percent (15/29) of patients were pTa/pT1 in cohort 1, and 42% (8/19) in cohort 2. No severe immunotherapy-mediated toxicity was observed. Four patients had chemotherapy-related grade 3 neutropenia, one grade 4; one patient had grade 3 thrombopenia, one grade 4; and four patients had grade 3 anemia. CONCLUSION: Although our negative study did not meet its primary end point in either cohort, the combination of durvalumab and platin-based chemotherapy, especially cisplatin, showed promising results in terms of downstaging. The safety profile was good and the surgical risk was not increased.
- 1 May 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (13) , 1578-1586
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial
PURPOSE: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin + gemcitabine) in combination with durvalumab in these patients. PATIENTS AND METHODS: This phase II trial (ClinicalTrials.gov identifier: NCT04617756 ) included patients with nonmetastatic, high-grade UTUC, on the basis of the ureteroscopic biopsy or urine cytology, and/or infiltrative aspect of the renal pelvis/ureteral wall by computed tomography imaging. Before RNU, patients received durvalumab plus gemcitabine/cisplatin (cohort 1) or durvalumab plus gemcitabine/carboplatin (cohort 2) once every 3 weeks for a total of four cycles (cohort choice on the basis of the glomerular filtration rate). The primary objective was the pathologic complete response (ypT0) rate in each cohort. RESULTS: Fifty patients were enrolled between 2021 and 2024 (31 in cohort 1; 19 in cohort 2). Median age was 68 years (range, 38-79), and 59% were men. Forty-five patients received four cycles of treatment, three patients three cycles, and one patient two cycles. Five patients switched to carboplatin during treatment. At surgery (N = 45 patients), rates of pT0 were 13% (4/29) in cohort 1 and 5% (1/19) in cohort 2. Fifty percent (15/29) of patients were pTa/pT1 in cohort 1, and 42% (8/19) in cohort 2. No severe immunotherapy-mediated toxicity was observed. Four patients had chemotherapy-related grade 3 neutropenia, one grade 4; one patient had grade 3 thrombopenia, one grade 4; and four patients had grade 3 anemia. CONCLUSION: Although our negative study did not meet its primary end point in either cohort, the combination of durvalumab and platin-based chemotherapy, especially cisplatin, showed promising results in terms of downstaging. The safety profile was good and the surgical risk was not increased.
- 7 August 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (1) , 165-172
Hospitalization cost of Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC)
- 7 August 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (1) , 165-172
Hospitalization cost of Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC)
- Open Access
- 1 January 2022
- Published by INSTICC
- p. 281-288
Combined Medical Devices: Which Classification for These Borderline Products and Which Consequences for the Manufacturers - About a Use Case in Skin Healing Area
- 1 January 2022
- Published by INSTICC
- p. 281-288
Open AccessCombined Medical Devices: Which Classification for These Borderline Products and Which Consequences for the Manufacturers - About a Use Case in Skin Healing Area
- 1 July 2020
- Published by Elsevier in International Journal of Nursing Studies
- Vol. 107, 103547
Comments on “A multicentre prospective randomized controlled clinical trial comparing the effectiveness and cost of a static air mattress and alternating air pressure mattress to prevent pressure ulcers in nursing home residents”: Letter to the editor and authors’ reponse
- 1 July 2020
- Published by Elsevier in International Journal of Nursing Studies
- Vol. 107, 103547
Comments on “A multicentre prospective randomized controlled clinical trial comparing the effectiveness and cost of a static air mattress and alternating air pressure mattress to prevent pressure ulcers in nursing home residents”: Letter to the editor and authors’ reponse